Techno Medica Co Ltd

Techno Medica maintains a strong liquidity position with cash and equivalents amounting to ¥9,061,387,000, representing 50.5% of total assets. The company's liquidity FPT score is high, supported by a current ratio of 4.79 and no long-term debt, indicating minimal refinancing risk. Profitability metrics show a return on equity (ROE) of 6.98% and return on assets (ROA) of 5.6%, both below the industry median for medical equipment firms. Gross margin stands at 49.7%, while operating margin is 13.3%, suggesting moderate efficiency in converting revenue to profit. The company's revenue is concentrated in three core segments: blood collection tube preparation, laboratory test apparatus, and consumable goods. No geographic breakdown is available, but the firm operates primarily in Japan, with export activities noted in its business description. Outlook for the current fiscal year shows stable revenue growth, with a projected increase of 2.1% year-over-year. Free cash flow of ¥602,509,000 supports reinvestment or shareholder returns, though capital expenditures remain minimal at -¥31,566,000. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.0, and shares outstanding remain unchanged between basic and diluted measures, suggesting no near-term dilution pressure. Recent filings and transcripts do not disclose material events affecting operations or strategy. The company's focus remains on core medical equipment and consumables, with no significant M&A or restructuring activity reported in the latest disclosures.